1. Thakur JS, Paika R. Determinants of Smokeless Tobacco use in India. Indian J Med Res. 2018; 148:41–5. PMid: 30264753 PMCid: PMC6172920. https://doi.org/10.4103/ ijmr.IJMR_27_18.
2. IARC [International Agency for Research on Cancer]. Betelquid and areca-nut chewing and some areca-nut-derived nitrosamines, IARC monographs on the evaluation of carcinogenic risks to humans, Lyon, France; 2004; 85. 2020. https://publications.iarc.fr/103.
3. SCENIHR [Scientific Committee on Emerging and Newly Identified Health Risks]. Scientific opinion on Health effects of Smokeless Tobacco products, European Commission, 2008. 2020. http://ec.europa.eu/health/archive/ph_risk/committees/04_scenihr/docs/scenihr_o_013.pdf.
4. Stanfill SB, Connolly GN, Zhang L, Jia LT, Henningfield JE, Richter P, Lawler TS, Yusuf OA, Ashley DL, Watson CH. Global surveillance of oral tobacco products: Total nicotine, unionised nicotine and tobacco-specific N-nitrosamines. Tob Control. 2011; 20(3):e2. PMid: 21109685. https://doi.org/10.1136/tc.2010.037465.
5. IARC [International Agency for Research on Cancer]. Smokeless Tobacco and some tobacco-specific N-nitrosamines, IARC monographs on the evaluation of carcinogenic risks to humans, Lyon, France. 2007; 89. 2020. http://monographs.iarc.fr/ENG/Monographs/vol89/index. php.